scispace - formally typeset
Search or ask a question
Topic

Solid lipid nanoparticle

About: Solid lipid nanoparticle is a research topic. Over the lifetime, 3175 publications have been published within this topic receiving 127912 citations. The topic is also known as: LNP & SLN.


Papers
More filters
Journal ArticleDOI
TL;DR: The aim of this study was to improve the physicochemical stability of β-carotene by encapsulating into solid lipid nanoparticles (SLNPs) containing palmitic acid and corn oil, stabilized using whey protein isolate (WPI).

78 citations

Journal ArticleDOI
TL;DR: It is concluded that the biodegradable SLN stabilized with Tween 80 can potentially be used as drug carriers to the blood-brain barrier having a relatively long residence time in the blood stream.
Abstract: The plasma proteins adsorbing onto intravenously injected carriers are considered to be crucial factors determining the organ distribution. Plasma protein adsorption patterns were analyzed on solid lipid nanoparticles (SLN) stabilized with Tween 80 or stabilized with poloxamer 188. The binding patterns were determined by applying two different sample preparation methods, i.e. removal of the SLN from the plasma by (a) centrifugation and (b) gel filtration to assess, if the separation method has an effect on the patterns obtained. The Tween 80-modified SLN adsorbed the major plasma proteins known from particles with blood-brain barrier specificity. Poloxamer 188-surface modified SLN adsorbed the proteins known from model particles that exhibit prolonged circulation time in the blood. It is concluded that the biodegradable SLN stabilized with Tween 80 can potentially be used as drug carriers to the blood-brain barrier having a relatively long residence time in the blood stream. For the poloxamer 188-stabilized SLN a relatively long resistance time in the blood is predicted leading to potential accumulation in the bone marrow when looking at the distinct CII/CIII adsorption.

77 citations

Journal ArticleDOI
TL;DR: The intranasal administration of agomelatine solid lipid nanoparticles has effectively enhanced both the absolute bioavailability and the brain delivery of Agomel atine.
Abstract: Purpose Agomelatine is a novel antidepressant drug suffering from an extensive first-pass metabolism leading to a diminished absolute bioavailability. The aim of the study is: first to enhance its absolute bioavailability, and second to increase its brain delivery. Methods To achieve these aims, the nasal route was adopted to exploit first its avoidance of the hepatic first-pass metabolism to increase the absolute bioavailability, and second the direct nose-to-brain pathway to enhance the brain drug delivery. Solid lipid nanoparticles were selected as a drug delivery system to enhance agomelatine permeability across the blood-brain barrier and therefore its brain delivery. Results The optimum solid lipid nanoparticles have a particle size of 167.70 nm ±0.42, zeta potential of -17.90 mV ±2.70, polydispersity index of 0.12±0.10, entrapment efficiency % of 91.25%±1.70%, the percentage released after 1 h of 35.40%±1.13% and the percentage released after 8 h of 80.87%±5.16%. The pharmacokinetic study of the optimized solid lipid nanoparticles revealed a significant increase in each of the plasma peak concentration, the AUC(0-360 min) and the absolute bioavailability compared to that of the oral suspension of Valdoxan® with the values of 759.00 ng/mL, 7,805.69 ng⋅min/mL and 44.44%, respectively. The optimized solid lipid nanoparticles gave a drug-targeting efficiency of 190.02, which revealed more successful brain targeting by the intranasal route compared with the intravenous route. The optimized solid lipid nanoparticles had a direct transport percentage of 47.37, which indicates a significant contribution of the direct nose-to-brain pathway in the brain drug delivery. Conclusion The intranasal administration of agomelatine solid lipid nanoparticles has effectively enhanced both the absolute bioavailability and the brain delivery of agomelatine.

77 citations

Journal ArticleDOI
TL;DR: The results showed that the saturated HM-lecithin was the key in controlling the crystallisation behaviour, and thereby enabled the formation of oxidatively and physically stable lipid nanoparticles.

77 citations

Journal ArticleDOI
TL;DR: It is expected that patients will benefit from the advantages of lipid nanoparticle-based formulations, via the nasal/intranasal route, which bypasses the blood-brain barrier (BBB), avoiding first-pass metabolism and gastrointestinal degradation.
Abstract: Studies on the development of drug delivery systems have increased because these systems have particular characteristics that allow them to improve therapeutics. Among these, lipid nanoparticles (solid lipid nanoparticles, SLNs; and nanostructured lipid carriers, NLCs) have demonstrated suitability for drug targeting. The nasal administration of drug-loaded lipid nanoparticles showed effectiveness in treating central nervous system (CNS) disorders, particularly neurodegenerative diseases, because the nasal route (also called intranasal route) allows direct nose-to-brain drug delivery by means of lipid nanoparticles. Nonetheless, the feasibility of this application remains an open field for researchers. Drawbacks must be overcome before reaching the clinic (e.g., drug absorption at subtherapeutic levels, rapid mucociliary clearance). The intranasal administration of drugs for systemic absorption is effective for treating other conditions, such as cardiovascular diseases, infections, severe pain, and menopausal syndrome. In the near future, it is expected that patients will benefit from the advantages of lipid nanoparticle-based formulations, via the nasal/intranasal route, which bypasses the blood-brain barrier (BBB), avoiding first-pass metabolism and gastrointestinal degradation. This review discusses the use of SLNs and NLCs for nasal drug administration. A brief description of the nasal route and the features of SLNs and NLCs is initially provided.

77 citations


Network Information
Related Topics (5)
Drug carrier
18.2K papers, 997.7K citations
90% related
Drug delivery
49.7K papers, 1.8M citations
90% related
Micelle
35.1K papers, 1M citations
79% related
Self-healing hydrogels
34.9K papers, 1.2M citations
77% related
Nanoparticle
85.9K papers, 2.6M citations
76% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
2023193
2022446
2021242
2020254
2019237
2018226